TAS 2023 Asthma, Allergy and Immunology Conference
The Toledo Asthma, Allergy and Immunology's 2023 Conference seeks to improve the quality of care provided to patients with allergy, asthma, and immunologic disorders through a variety of lectures on Pediatric Asthma, Eosinophilia, Atopic Dermatitis, Biologics and more. We look forward to the exchange of knowledge and experiences among our members as they progress in their medical fields. Join us as we increase awareness among physicians, allied health professionals, and the general public about the subspecialty of allergy, asthma, and immunology.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Toledo Allergy Society (TAS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary care physicians
Allied healthcare professionals
At the conclusion of this activity learners should be able to…
1. Review pediatric asthma phenotypes and severity
2. Discuss knowledge of current pediatric asthma management in clinical practice.
3. Demonstrate knowledge of pediatric allergen immunotherapy.
4. Demonstrate understanding of common causes of eosinophilia.
5. Review the gastrointestinal effects of eosinophilia.
6. Evaluate the treatment management of eosinophilia with gastrointestinal disorders.
7. Review common types of atopic dermatitis in clinical practice.
8. Describe different clinical presentations of atopic dermatitis.
9. Review appropriate workup and management of a patient with atopic dermatitis.
10. Identify the use of approved biologicals for allergic diseases.
11. Discuss the benefits and risks associated with biologicals
12. Review appropriate management of different types of biologicals.
13. Identify allergic conditions that have been addressed by other specialties.
Toledo Allergy Society - Allergy, Asthma, and Immunology Conference
September 20, 2023
7:00 am - 7:45 am Registration / Breakfast
7:45 am - 8:00 am Welcome & Introductions, S. Maseeh Rehman, MD, President, Toledo Allergy Society
8:00 am - 9.00 am Pediatric Asthma Ian Slack, MD
9.00 am - 10.00 am Eosinophilia/Eosinophilic Gastrointestinal Disorders Joshua B. Wechsler, MD, MSCI
10:00 am - 10:30 am Break & Exhibits
10:30 am - 11.30 am Atopic Dermatitis Update Jennifer Mancusco, MD
11:30 am - 12:30 pm Biologics in Allergic Disease, Priya Bansal, MD
12:30 pm - 1:15 pm Lunch & Exhibits
1:15pm - 2:15 pm Potpourri in Allergy, Syed M Rehman, MD
2:15 pm - 2:30 pm Break & Exhibits
2:30 pm - 4:15 pm PBL Break Out Sessions
1. Patch Testing for Allergic Disorders – UM Fellow & Sara Ellingwood, MD
2. When & How to Test for Food Allergies – George Freigh, MD & Marc McMorris, MD
3. Management of Allergic Conditions in Pregnancy – UM Fellow & Deborah Lee, MD
4:15 - 4:45 pm Questions & Answers, Syed M Rehman, MD
4:45 - 5:00 pm Closing Remarks & Adjourn, Syed M Rehman, MD
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with ineligible companies have been mitigated.
Syed Rehman, MD, Planner/Speaker
Speaker: Takeda, GSK/Grifols
Researcher: Takeda, AZ, Sanofi/Salvista, Enanta/Leo, Novartis, Genentech, Cue Health Claire Diagnostics
Stock Owner: Pfizer, Bristol Myers
Ian Slack, MD, Speaker
Advisor: Alladapt Immunotherapeutics
Joshua Wechsler, Md, MSCI, Speaker
Advisor: Ellodi, Regeneron/Sanofi, Bristol Myers Squibb, Allakos, InvenAl,
Clinical Trial Funding: Regeneron/Sanofi, Allakos
Research Funding: InvenAI, Researched Nutritionals
Priya Bansal, MD, Speaker
Advisor: AstraZeneca, GSK, Sanofi/Regeneron, Novartis
Speaker: AstraZeneca, GSK, Sanofi/Regeneron
Consultant: AstraZeneca, GSK, Sanofi/Regeneron
The following have no relevant financial relationships with ineligible companies to disclose:
Svetlana Kriegel, MD, Planner
Tammy Guastella, CMP, Planner
George Freigeh, MD, Speaker
Jennifer Mancuso, MD, Speaker
Marc McMorris, MD, Speaker
Ryan Din, MD, Speaker
Sara Ellingwood, MD, Speaker
Fatema Mollah, MD, Speaker
Deborah Lee, MD, Speaker
- 7.50 AMA PRA Category 1 Credit™
- 7.50 Attendance